Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer

Autor Cheng, Derek K., Oni, Tobiloba E., Thalappillil, Jennifer S., Park, Youngkyu, Ting, Hsiu-Chi, Alagesan, Brinda, Prasad, Nadia V., Addison, Kenneth, Rivera, Keith D., Pappin, Darryl J., Van Aelst, Linda, Tuveson, David A.
Vydáno v Proc Natl Acad Sci U S A (2021)

Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival

Autor Markowitz, Geoffrey J., Havel, Lauren S., Crowley, Michael J.P., Ban, Yi, Lee, Sharrell B., Thalappillil, Jennifer S., Narula, Navneet, Bhinder, Bhavneet, Elemento, Olivier, Wong, Stephen T.C., Gao, Dingcheng, Altorki, Nasser K., Mittal, Vivek
Vydáno v JCI Insight (2018)